This website is using cookies

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive cookies. I ACCEPT Learn More

The Central Bank of Ireland ("CBI") has today, 19 September 2014, issued a consultation paper ("CP86") on measures designed to enhance the effectiveness of fund management company boards. Within its scope of review are the boards of: (i) self-managed investment companies (UCITS or AIF); (ii) UCITS management companies; and (iii) Irish AIFMs. 

This consultation follows a recently completed governance review initiated by the CBI with the participation of certain industry representatives. The consultation closes on 12 December 2014

Based on Maples and Calder's initial review, it seems clear that the consultation, once complete, will result in new regulatory guidance measures in relation to the following areas:

(a) Delegation arrangements - New, prescribed requirements for: (i) initial and ongoing oversight of investment management functions; (ii) distribution and marketing activities; and (iii) risk management functions.

(b) Key management functions - Streamlining current 10/16 key management functions - to be consolidated (for both UCITS management companies and AIFMs) into six key management functions with more detail on what each function must entail.

(c) Board composition - Adjustments to Irish resident director/independence requirements; new requirements on board expertise and collective composition.

The CBI's aim in undertaking this review is to support the continuous improvement of fund management company effectiveness. We will consider the prudential merits of any measures that emerge from the consultation in due course. Of immediate concern will be the timing of this review. Coming so shortly after the successful, but operationally burdensome, implementation of AIFMD, this is unlikely to be welcomed by operators of Irish funds who were hoping for a period without further regulatory change. 

A copy of CP86 is available here. If you would like to discuss the substance of the consultation in more detail, and get our insight and perspective, please feel free to contact any of the investment funds partners listed above, or your usual Maples and Calder contact.

CONTACTS

bioImage

Peter Stapleton

Partner

+353 1 619 2024

bioImage

Stephen Carty

Partner

+353 1 619 2023

bioImage

Adam Donoghue

Partner

+44 20 7466 1711

*
*
*
*

Please note that your email may be received and read by other Maples Group lawyers in addition to your intended recipient.

Thank you!

Thank you for your enquiry. Someone will respond to you shortly.

Connect

Want to get in touch ?

Contact Us